#China #Hefei #Multiple Myeloma #Kangpu Biopharmaceuticals #KPG-818

Kangpu Biopharmaceuticals Secures IND Approval for KPG-818

In an important milestone for the medical community, Kangpu Biopharmaceuticals, Ltd. (Kangpu) has successfully received Investigational New Drug (IND) approval for its innovative product, KPG-818, from the Center for Drug Evaluation (CDE) under the China National Medical Products Administration (NMPA). This approval is directed toward treating patients suffering from relapsed/refractory multiple myeloma (RRMM).

What is KPG-818?
KPG-818 is a pioneering oral treatment, classified as a molecular glue modulator that specifically targets the E3 ubiquitin ligase complex known as CRL4-CRBN. Through its mechanism, KPG-818 shows a commendable ability to bind to cereblon (CRBN) with high affinity and effectively degrades Aiolos (IKZF3) and Ikaros (IKZF1)—two critical transcription factors governing B-cell development. The implications of such capabilities include an array of immunomodulatory, anti-angiogenic, and anti-tumor benefits, marking KPG-818 as a significant advancement in therapies for hematological cancers.

Kangpu's extensive research led to the completion of a Phase I clinical trial in the United States, involving patients with various hematological malignancies. The findings so far have been encouraging, particularly for those with RRMM who had already undergone extensive previous treatments including two immunomodulatory drugs (like lenalidomide and pomalidomide), at least one proteasome inhibitor (bortezomib, ixazomib, or carfilzomib), and a CD38 monoclonal antibody (such as daratumumab or isatuximab).

The initial results indicate good safety levels and tolerability among the participants, alongside promising pharmacokinetic properties and therapeutic effects, suggesting that KPG-818 could be a game-changer in the treatment landscape for RRMM.

About Kangpu Biopharmaceuticals

Kangpu Biopharmaceuticals, established in Hefei, China, is at the cutting edge of biopharmaceutical development. The company focuses on innovating therapeutic solutions addressing complex medical challenges, including solid tumors, autoimmune illnesses, and inflammatory disorders. Their research is grounded in advanced technological platforms such as NeoMIDES®, gDACs®, and X-SYNERGY®, underscoring their dedication to creating first-in-class and best-in-class drug candidates.

In addition to KPG-818, Kangpu Biopharmaceuticals continues to expand its pipeline, aiming to revolutionize treatment methodologies and improve patient outcomes across various diseases.

For more information on Kangpu Biopharmaceuticals and its innovative drug candidates, visit KangpuGroup.com.
Source: Kangpu Biopharmaceuticals